|Mr. Peter Goldschmidt||Chairman of the Exec. Board & CEO||1.25M||N/A||1964|
|Mr. Miguel Pagan Fernandez||CTO & Member of Exec. Board||584k||N/A||1965|
|Dr. Wolfgang Ollig||Group Chief Financial Officer & Member of Exec. Board||N/A||N/A||N/A|
|Dr. Christoph Dengler||Exec. VP of Global Legal||N/A||N/A||N/A|
|Mr. Frank Staud||Exec. VP of Global Communications & Branding||N/A||N/A||N/A|
|Ms. Simone Berger||Exec. VP of Global HR||N/A||N/A||1979|
|Mr. Carsten Cron||Exec. VP of Emerging Markets||N/A||N/A||N/A|
|Mr. Eelco Ockers||Exec. VP of Germany||N/A||N/A||N/A|
|Mr. Roger Scarlett-Smith||Exec. VP UK & US||N/A||N/A||1960|
|Dr. Steffen Wagner||Exec. VP of European Markets||N/A||N/A||N/A|
STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; and Omeprazol and Pantoprazol for gastric ulcer/reflux. The Branded Products segment offers Bortezomib STADA for cancer; APO-Go for Parkinson's disease; Grippostad for cold; Zoflora for disinfections; and Snup for head cold. The company serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. It has strategic partnership with XBrane Biopharma for the development of biosimilars; and Alvotech ehf for the marketing of biosimilars. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.
STADA Arzneimittel Aktiengesellschaft’s ISS governance QualityScore as of 1 November 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 1; Compensation: 8.